TLR4 and serum lipopolysaccharide activity: A new humanized antibody against the antigen has been shown to inhibit endotoxin-mediated Toll-like receptor 4 (TLR4) activation better than polymyxin B in vitro, as well as improve survival in endotoxemia-susceptible mice (6).